TY - JOUR
T1 - Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia
T2 - experience of the European Leukemianet MRD Working Party
AU - Tettero, Jesse M
AU - Freeman, Sylvie
AU - Buecklein, Veit
AU - Venditti, Adriano
AU - Maurillo, Luca
AU - Kern, Wolfgang
AU - Walter, Roland B
AU - Wood, Brent L
AU - Roumier, Christophe
AU - Philippé, Jan
AU - Denys, Barbara
AU - Jorgensen, Jeffrey L
AU - Bene, Marie C
AU - Lacombe, Francis
AU - Plesa, Adriana
AU - Guzman, Monica L
AU - Wierzbowska, Agnieszka
AU - Czyz, Anna
AU - Ngai, Lok Lam
AU - Schwarzer, Adrian
AU - Bachas, Costa
AU - Cloos, Jacqueline
AU - Subklewe, Marion
AU - Fuering-Buske, Michaela
AU - Buccisano, Francesco
N1 - Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the European Hematology Association.
PY - 2022/1
Y1 - 2022/1
N2 - Measurable residual disease (MRD) quantified by multiparameter flow cytometry (MFC) is a strong and independent prognostic factor in acute myeloid leukemia (AML). However, several technical factors may affect the final read-out of the assay. Experts from the MRD Working Party of the European LeukemiaNet evaluated which aspects are crucial for accurate MFC-MRD measurement. Here, we report on the agreement, obtained via a combination of a cross-sectional questionnaire, live discussions, and a Delphi poll. The recommendations consist of several key issues from bone marrow sampling to final laboratory reporting to ensure quality and reproducibility of results. Furthermore, the experiences were tested by comparing two 8-color MRD panels in multiple laboratories. The results presented here underscore the feasibility and the utility of a harmonized theoretical and practical MFC-MRD assessment and are a next step toward further harmonization.
AB - Measurable residual disease (MRD) quantified by multiparameter flow cytometry (MFC) is a strong and independent prognostic factor in acute myeloid leukemia (AML). However, several technical factors may affect the final read-out of the assay. Experts from the MRD Working Party of the European LeukemiaNet evaluated which aspects are crucial for accurate MFC-MRD measurement. Here, we report on the agreement, obtained via a combination of a cross-sectional questionnaire, live discussions, and a Delphi poll. The recommendations consist of several key issues from bone marrow sampling to final laboratory reporting to ensure quality and reproducibility of results. Furthermore, the experiences were tested by comparing two 8-color MRD panels in multiple laboratories. The results presented here underscore the feasibility and the utility of a harmonized theoretical and practical MFC-MRD assessment and are a next step toward further harmonization.
UR - http://www.scopus.com/inward/record.url?scp=85122298387&partnerID=8YFLogxK
U2 - 10.1097/HS9.0000000000000676
DO - 10.1097/HS9.0000000000000676
M3 - Article
C2 - 34964040
SN - 2572-9241
VL - 6
SP - E676
JO - HemaSphere
JF - HemaSphere
IS - 1
M1 - e676
ER -